{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:51Z","timestamp":1761870831327,"version":"build-2065373602"},"reference-count":111,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clml.2015.07.644","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T23:20:09Z","timestamp":1438816809000},"page":"728-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Systemic Mastocytosis: Clinical Update and Future Directions"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-6953","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-8090","authenticated-orcid":false,"given":"Nicole","family":"Carreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.07.644_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","article-title":"Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non\u2013mast cell hematopoietic neoplasms","volume":"114","author":"Valent","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib2","first-page":"166","article-title":"Beitr\u00e4ge zur Kenntnis der granulierten Bindegewebszellen und der eosino-philen Leukozyten","volume":"3","author":"Ehrlich","year":"1879","journal-title":"Arch Anat Physiol"},{"key":"10.1016\/j.clml.2015.07.644_bib3","first-page":"426","article-title":"Urticaria pigmentosa; a report of a case with autopsy","volume":"48","author":"Ellis","year":"1949","journal-title":"Arch Pathol"},{"key":"10.1016\/j.clml.2015.07.644_bib4","first-page":"385","article-title":"Biology, classification and treatment of human mastocytosis","volume":"108","author":"Valent","year":"1996","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.clml.2015.07.644_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib6","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"54","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"key":"10.1016\/j.clml.2015.07.644_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000085563","article-title":"Clonality and molecular pathogenesis of mastocytosis","volume":"114","author":"Akin","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2015.07.644_bib8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2015.07.644_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib10","doi-asserted-by":"crossref","first-page":"e1002068","DOI":"10.1371\/journal.pcbi.1002068","article-title":"Mutation D816V alters the internal structure and dynamics of C-Kit receptor cytoplasmic region: implications for dimerization and activation mechanisms","volume":"7","author":"Laine","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.clml.2015.07.644_bib11","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.644_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.644_bib14","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.07.644_bib16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","volume":"99","author":"Cit\u00e9","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.07.644_bib17","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib18","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clml.2015.07.644_bib19","first-page":"S8","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report","volume":"111","author":"Jaffe","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2015.07.644_bib20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0889-8588(05)70303-8","article-title":"A\u00a0proposed classification of mastocytosis incorporating molecular genetics","volume":"14","author":"Longley","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.07.644_bib22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1398-9995.1988.tb00914.x","article-title":"Human bone marrow mast cells in systemic mast cell disease ultrastructure and evaluation of fixation and staining techniques","volume":"43","author":"Gabriel","year":"1988","journal-title":"Allergy"},{"key":"10.1016\/j.clml.2015.07.644_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0889-8588(03)00089-3","article-title":"Mast cell proliferative disorders: current view on variants recognized by the World Health Organization","volume":"17","author":"Valent","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non\u2013mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.07.644_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0889-8588(05)70296-3","article-title":"Hematologic aspects of systemic mastocytosis","volume":"14","author":"Parker","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"year":"2008","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","key":"10.1016\/j.clml.2015.07.644_bib28"},{"key":"10.1016\/j.clml.2015.07.644_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clml.2015.07.644_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0091-6749(05)80132-0","article-title":"Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy","volume":"86","author":"Frieri","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","article-title":"Mast cell leukemia: report of a case and review of the literature","volume":"61","author":"Travis","year":"1986","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2015.07.644_bib32","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.07.644_bib34","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2009-12-259085","article-title":"Proposal for a revised classification of systemic mastocytosis","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2010-05-285270","article-title":"The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non\u2013mast cell lineage disease (SM-AHNMD)","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib36","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"Van Doormaal","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","article-title":"Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Pardanani","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0889-8588(05)70295-1","article-title":"Mastocytosis and the skin","volume":"14","author":"Soter","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.clml.2015.07.644_bib41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(05)70298-7","article-title":"Gastrointestinal abnormalities and involvement in systemic mastocytosis","volume":"14","author":"Jensen","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib43","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clml.2015.07.644_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"Van Der Veer","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.clml.2015.07.644_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.iac.2014.02.001","article-title":"Neuropsychological features of adult mastocytosis","volume":"34","author":"Moura","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib46","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.07.644_bib47","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0002-9343(91)90214-I","article-title":"Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis","volume":"91","author":"Lawrence","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2015.07.644_bib48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.1990.tb07870.x","article-title":"Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders","volume":"76","author":"Horny","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.07.644_bib49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1757-1626-1-100","article-title":"An unusual cause of spontaneous bleeding in the intensive care unit\u2014mastocytosis: a case report","volume":"1","author":"Koenig","year":"2008","journal-title":"Cases J"},{"key":"10.1016\/j.clml.2015.07.644_bib50","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1097\/00007632-200404150-00025","article-title":"Acute spinal epidural hematoma and systemic mastocytosis","volume":"29","author":"Arias","year":"2004","journal-title":"Spine"},{"key":"10.1016\/j.clml.2015.07.644_bib51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1076029607309173","article-title":"Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis","volume":"14","author":"Sucker","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clml.2015.07.644_bib52","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1074\/jbc.M111.325712","article-title":"Mast cell restricted mouse and human tryptase\u00b7heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen","volume":"287","author":"Prieto-Garc\u00eda","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2015.07.644_bib53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0889-8588(05)70297-5","article-title":"Lymphoid tissues and the immune system in mastocytosis","volume":"14","author":"Mekori","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib54","first-page":"1163","article-title":"Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases","volume":"22","author":"Mican","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2015.07.644_bib55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000048184","article-title":"Surrogate markers of disease in mastocytosis","volume":"127","author":"Akin","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048180","article-title":"Histopathological and immunohistochemical aspects of mastocytosis","volume":"127","author":"Horny","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib59","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0145-2126(01)00050-9","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classi cation of adult mastocytosis","volume":"25","author":"Escribano","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib62","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.07.644_bib64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder\u2013associated clinical sequelae of excessive prostaglandin D2 production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib65","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib66","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib67","doi-asserted-by":"crossref","unstructured":"Lieberoth S, Thomsen SF, Presentation C. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab, Case Rep Med 2015; 2015, 903541.","DOI":"10.1155\/2015\/903541"},{"key":"10.1016\/j.clml.2015.07.644_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clml.2015.07.644_bib69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clml.2015.07.644_bib70","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","article-title":"Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE","volume":"104","author":"Kontou-Fili","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clml.2015.07.644_bib71","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib72","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib73","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib74","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome\u2013negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.07.644_bib75","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Giles FJ, et\u00a0al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol, 2015. [e-pub ahead of print].","DOI":"10.1007\/s00432-015-1988-0"},{"key":"10.1016\/j.clml.2015.07.644_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib78","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.leukres.2008.06.013","article-title":"Lenalidomide therapy in systemic mastocytosis","volume":"33","author":"Kluin-Nelemans","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib79","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.644_bib80","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group\u2013Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00663015","article-title":"Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b","volume":"72","author":"Weide","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.07.644_bib82","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib83","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib84","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.07.644_bib85","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.1995.tb08689.x","article-title":"Interferon-\u03b1 in combination with corticosteroids improves systemic mast cell disease","volume":"132","author":"Delaporte","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.07.644_bib86","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib87","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1172\/JCI114865","article-title":"Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in\u00a0vitro and in\u00a0vivo: a novel approach to immunosuppressive therapy","volume":"86","author":"Carrera","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2015.07.644_bib88","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib89","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.07.644_bib90","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib91","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A\u00a0novel K509I mutation of KIT identified in familial mastocytosis - In\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib92","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib93","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.07.644_bib94","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.07.644_bib95","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clml.2015.07.644_bib96","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.644_bib97","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib98","first-page":"17","article-title":"PKC412\u2014a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.clml.2015.07.644_bib99","first-page":"124","article-title":"Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2 CPKC412D2201 Trial","author":"Gotlib","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib101","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib102","first-page":"8","article-title":"FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H","volume":"3","author":"Valent","year":"2014","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2015.07.644_bib103","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A\u00a0pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.07.644_bib104","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","article-title":"Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation","volume":"34","author":"Spyridonidis","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2015.07.644_bib105","first-page":"124","article-title":"Gain-of-function KIT mutations sensitize the mutant isoform to the type I tyrosine kinase inhibitor crenolanib: a rationale for the therapeutic use in systemic mastocytosis (SM) and core binding factor leukemias (CBFL)","author":"Schittenhelm","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib106","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib107","first-page":"1","article-title":"Aberrant expression of CD123 (interleukin-3 receptor-\u03b1) on neoplastic mast cells","volume":"123","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.644_bib108","first-page":"122","article-title":"SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), possesses preclinical cytotoxic activity against chronic eosinophilic leukemia","author":"Brooks","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib109","first-page":"120","article-title":"SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML","author":"Konopleva","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.644_bib110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.iac.2014.01.006","article-title":"CD30 in systemic mastocytosis","volume":"34","author":"Van Anrooij","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.clml.2015.07.644_bib111","first-page":"124","article-title":"First selective KIT D816V inhibitor for patients with systemic mastocytosis","author":"Evans","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:42Z","timestamp":1761870462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015010769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":111,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S2152265015010769"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.644","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Mastocytosis: Clinical Update and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}